drugset / Trial / NCT01307436

Long Term Follow-up of a Study to Assess the Safety and Immunogenicity of a Hepatitis A Vaccine Administered With and in the Absence of DTPaHibIPV, OPV and MMR Vaccines

NCT01307436

Phase 3 Completed 327 enrolled Crucell Holland BV
RandomizedParallel-groupOpen-labelPrevention

Summary

The primary purpose of this study was to assess whether the protection afforded by Epaxal vaccine co-administered with diphtheria, tetanus, Bordetella pertussis, Haemophilus influenzae type b, and inactivated polio vaccine(DTPaHibIPV), oral polio vaccine (OPV) and (measles mumps and rubella) MMR vaccines against hepatitis A was not inferior to the protection afforded by Epaxal administered alone. The aim of the follow-up phase is to obtain information on the long term protection afforded by Epaxal, and to compare this with an alternative hepatitis A vaccine (Havrix).

Timeline

Start
2007-03-14
Primary completion
2013-07-08
Completion
2013-07-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Epaxal Vaccine 0.25 ml
Comparator HAVRIX 720 Vaccine 0.5 ml